Local analgesic effects of exogenous opioid agonists are particularly prominent in painful inflammatory conditions and are mediated by opioid receptors on peripheral sensory nerves. The endogenous ligands of these receptors, opioid peptides, have been demonstrated in resident immune cells within inflamed tissue of animals and humans. Here we eamine in vivo and in vitro whether interleukin 1P (IL-1) or corticotropin-releasing factor (CRF) is capable of releasing these endogenous opiolds and inhibiting pain. When uijected into inflamed rat paws (but not intravenously), IL-1 and CRF produce antinociception, which is reversible by IL-1 receptor antagonist and a-helical CRF, respectively, and by the immunosuppressant cyclosporine A. In vivo administration of antibodies against opioid peptides indicates that the effects of IL-1 and CRF are mediated by 3-endorphin and, in addition, by dynorphin A and [Met]enkephalin, respectively. Correspondingly, IL-1 effects are inhibited by p-, 8., and oc-opioid antagonists, whereas CRF effects are attenuated by all except a tc-antagonist. Finally, IL-1 and CRF produce acute release of immunoreactive 13-endorphin in cell suspensions freshly prepared from inflamed lymph nodes. This effect is reversible by IL-1 receptor antagonist and a-helical CRF, respectively. These findings suggest that IL-1 and CRF activate their receptors on immune cells to release opioids that subsequently occupy multiple opioid receptors on sensory nerves and result in antinociception. (-Endorphin, p. and 8-opioid receptors play a major role, but IL-1 and CRF appear to differentially release additional opioid peptides.
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An increasing number of experimental and clinical studies demonstrate that locally administered opioid agonists elicit potent analgesic effects in inflamed tissue (for review, see refs. 1-3). They interact with opioid receptors that are present on peripheral sensory nerves and are apparently up-regulated during the development of inflammation (4) (5) (6) . Their endogenous ligands, opioid peptides, are found in resident immune cells within peripheral inflamed tissue (5, 7, 8) . These findings are consistent with studies demonstrating that opioid peptides are produced within immune cells in culture (9, 10) and suggest a functional link between the immune and sensory nervous systems. Indeed, such immunederived opioids [predominantly (-endorphin (/3END)] are apparently released during environmental stressful stimuli and result in the inhibition ofpain (5, 8, 11) . In view ofthe fact that opioid-containing cells have recently been demonstrated in human inflamed synovial tissue (11) , it becomes most interesting to find tools to liberate these pools of potentially analgesic substances.
The aim of the present experiments was to identify agents that inhibit pain by releasing opioid peptides from resident immune cells within inflamed tissue in vivo. Two substances, interleukin 13 (IL-1) and corticotropin-releasing factor (CRF), were of particular interest because they are secretagogues of /3-END in long-term cultured immune cells from healthy organisms (10) . In our model and in the clinical situation, however, immunocytes sustain a chronic pathophysiological stimulation due to persistent inflammation in vivo. Parallel ex vivo studies were therefore performed to demonstrate that these substances indeed cause 3-END release from inflamed immune cells with a kinetics similar to our algesiometric studies. In Vitro Rele Experiments. Four to 5 days after inoculation with Freund's complete adjuvant rats were euthanized by CO2 inhalation. Popliteal lymph nodes were removed and ground using a cell dissociation sieve (size 60 mesh; Sigma). Cells were reconstituted in 5-15 ml of Hanks' balanced salt solution (HBSS) and centrifuged at 1300 rpm for 10 min at 200C using a swinging bucket rotor. Cell pellets were then reconstituted in HBSS aiming at a concentration of0.05-0.15 x 106 cells per ml. Cell viability, as determined by the trypan blue exclusion method, was >95%. A 0.3-ml volume of this cell suspension was incubated with 0.1 ml of either HBSS, a-helical CRF (25-100 ng), or IL-ira (25-100 ng) at 3TC in a shaking waterbath. After 5 min 0.1 ml ofeitherHBSS, CRF (25- RIA. Assays were performed using a RIA kit (Peninsula Laboratories). Tubes were prepared in duplicate containing 0.1-ml standard concentrations of (3-END or unknown samples (except total count, nonspecific binding, and total binding tubes) dissolved in RIA buffer (containing 0.1 M sodium phosphate, 0.05 M NaCi, 0.01% NaN3, 0.1% bovine serum albumin, and 0.1% Triton X-100) and rabbit anti-3-END (0.1 ml) to be incubated overnight at 4°C. On day 2, 0.1 ml of 125I-labeled (-END (12,000-15,000 cpm) was added and tubes were incubated overnight at 4°C. On day 3, 0.1 ml of goat anti-rabbit IgG and 0.1 ml of normal rabbit serum were added and incubated for 90 min at room temperature. Subsequently, 0.5 ml of RIA buffer was added and tubes were spun at 3000 rpm for 20 min at 4°C in a microcentrifuge (Beckman). After aspiration of supernatants (except total count tubes), radioactivity in the pellets was counted.
MATERIALS AND METHODS
Data Analysis. PPT are given as raw values (means ± SEM) or (in dose-response curves) as percentage of maximum possible effect (% MPE) according to the following formula: (PPT postinjection -basal PPT)/(250 -basal PPT). Values in right (inflamed) paws were compared to those in left paws by the Wilcoxon paired-sample test. Independent groups (control experiments) were compared by the Mann-Whitney U test. In in vitro experiments the mean ± SEM of four to eight experiments, using one lymph node each, is given. For dose-response curves an analysis of variance (ANOVA) and a subsequent linear regression ANOVA were performed to test the zero slope hypothesis. Differences were considered significant if P < 0.05 (two-tailed).
RESULTS
Algesiometry. Experiment 1. Both IL-1 and CRF produced significant elevations of PPT in inflamed but not in noninflamed paws (Fig. 1) . PPT elevations were maximal at 5 min postinjection ( Fig. 1 ) and they were dose-dependent ( Fig.  2A) . Equivalent doses given i.v. were ineffective (IL-1, P = 0.27; CRF, P = 0.32; Wilcoxon test) (data not shown). In noninflamed paws PPT remained unchanged ( Fig. 2A) (Table 2) . Experiment 2. IL-1 effects on PPT were dose-dependently attenuated by anti-,B-END (P < 0.001) and anti-DYN (P < 0.05, linear regression ANOVA) but not by anti-ENK (P = 0.45; ANOVA) (Fig. 3A) . CRF effects on PPT were dosedependently inhibited by anti-p-END (P < 0.01) and anti-ENK (P < 0.05; linear regression ANOVA) but not by anti-DYN (P = 0.90; ANOVA) (Fig. 3B) . Normal rabbit IgG did not influence PPT elevations by IL-1 (P = 0.54) or CRF (P = 0.47; Mann-Whitney U test). All opioid receptor antagonists reversed the IL-1 effect dose-dependently (naloxone, P < 0.01; CTOP, P < 0.01; ICI 174,864, P < 0.001; nor-BNI, P < 0.05; linear regression ANOVA) (Fig. 3C) . The CRF effect was reversed by naloxone (P < 0.01), CTOP (P < 0.001), and ICI 174,864 (P < 0.001; linear regression ANOVA) but not by nor-BNI (P = 0.29; ANOVA) (Fig. 3D) .
In Vitro Release Experiments. Both IL-1 and CRF produced dose-dependent release of immunoreactive (ir) p-END from cell suspensions (IL-1, P < 0.005; CRF, P < 0.05; linear regression ANOVA) (Fig. 4) 
DISCUSSION
The first set of experiments demonstrates that both IL-1 and CRF can potently inhibit nociception in inflamed tissue by a peripheral mechanism of action. The fact that IL-1 and CRF effects are dose-dependent and selectively reversible by their' respective antagonists strongly suggests that these actions are mediated by IL-1 and CRF receptors, respectively. Within our observation period, neither agent alters nociceptive thresholds in noninflamed tissue or the swelling, indicating that the inflammatory process is necessary but that these antinociceptive effects do not occur via overt antiinflammatory actions. These findings extend previous reports of peripheral analgesic effects of CRF (14) but are in contrast to those of hyperalgesic effects induced by IL-1 (15) . The difference between our situation and the latter, in which hyperalgesia occurred 3 hr after injection of IL-1 into noninflamed tissue (15) , is clearly the presence offully developed inflammation at the time of IL-1 application. (16, 17) . To investigate the role of such cells in the mediation of IL-1-and CRF-induced analgesia, we pretreated rats with CsA, an immunosuppressant that inhibits the transcription of early genes involved in the activation of T cells and other immunocytes (5, 18 (5, 7, 8) . Investigations concerning the mechanisms of release of such peptides have shown that both IL-1 and CRF can stimulate release of (END (10, 24, 26) , an important endogenous ligand at peripheral opioid receptors (5, 27) . Therefore, we hypothesized that both agents could release opioid peptides, which then produce analgesia via activation of opioid receptors on nociceptive nerve terminals (4-6). Indeed, our second set of experiments demonstrates that both IL-1-and CRF-induced antinociception is attenuated by anti-(-END. In addition, anti-DYN and anti-ENK inhibit the effects ofIL-1 and CRF; respectively, indicating a differential release of opioids by the two agents. This is supported by the finding that different dose ranges of naloxone and different selective opioid antagonists reverse those agents' actions.
Thus, while the effect of CRF is mediated by pu-and 6-, but not by K-receptors, all three opioid receptor types are involved in IL-i's effect. Taken together, these results indicate that both agents release (END, which activates p.-and 6-receptors, consistent with our previous studies that have 50- shown that (-END is the prevailing endogenous ligand of peripheral opioid receptors (5, 27) . In addition, DYN (a K-ligand) and ENK (a 6-ligand) appear to be liberated by IL-1 and CRF, respectively.
To further confirm our hypothesis that both agents release 3-END from immune cells within the short time frame applied in our in vivo studies, we sought to mimic this situation in vitro. Indeed, both IL-1 and CRF produced release of ir-(3END in cell suspensions prepared freshly from inflamed lymph nodes. The fact that these effects are dosedependent and selectively reversible by the respective antagonists strongly indicates that they are mediated by IL-1 and CRF receptors. These findings substantially extend previous reports of (3-END release from immunocytes, since in those studies cells were obtained from healthy human volunteers and subjected to various long-term culture conditions (10, 24, 26 Considering that these results implicate (3-END as a predominant mediator of the analgesic effects triggered by IL-1 and CRF, the short duration of these effects, though consistent with our former studies (27) , is noteworthy. Although (3-END is relatively resistant to degradation at physiologic pH values in plasma and in the central nervous system, virtually nothing is known about its fate in the milieu of peripheral inflamed tissue. Particular to this milieu are, for example, a low pH and a high proteolytic activity (28) . However, the fact that the antinociception following a single injection of an exogenous peptide is short-lasting does not exclude the possibility that endogenous peptides, which may be continuously released in vivo, have effects of longer duration. Indeed, our clinical studies indicate that under postoperative conditions, locally mediated endogenous opioid analgesia is effective for several hours (11) .
In summary, we have found that IL-1 and CRF liberate (-END and, in addition, DYN and ENK within inflamed tissue. These opioid peptides interact with multiple opioid receptors on nociceptive nerve terminals to result in potent analgesia. These findings have several interesting implications: (i) Beyond its widely accepted role as a proinflammatory agent, IL-1 can locally generate analgesia, thus maintaining a delicate homeostasis during the healing process of injured tissue. (ii) We have discovered a mechanism for the previously unexplained peripheral antinociceptive actions of CRF (14) and a possible function of CRF produced in inflammatory sites (29) . (iii) Two possible mediators for our formerly described stress-induced analgesia in inflammation (5, 8, 27) 
